Loading…
New Biomarkers (Endocan, Interleukin-17, and Thrombospondin-4) for the Diagnosis, Assessment of Severity, and Follow-Up of Peripheral Arterial Disease
The present study evaluated the use of endocan, interleukin-17 (IL-17), and thrombospondin-4 (TSP-4) blood levels as potential biomarkers for the diagnosis and follow-up of peripheral arterial disease (PAD). Patients with PAD (Rutherford categories I, II, and III) who were admitted between March 202...
Saved in:
Published in: | Angiology 2023-08, Vol.74 (7), p.631-639 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403 |
---|---|
cites | cdi_FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403 |
container_end_page | 639 |
container_issue | 7 |
container_start_page | 631 |
container_title | Angiology |
container_volume | 74 |
creator | Yazman, Serkan Depboylu, Burak Can Saruhan, Ercan Cenikli, Utku Harmandar, Buğra Arslan, Kadir İlhan, Gökhan İştar, Hande |
description | The present study evaluated the use of endocan, interleukin-17 (IL-17), and thrombospondin-4 (TSP-4) blood levels as potential biomarkers for the diagnosis and follow-up of peripheral arterial disease (PAD). Patients with PAD (Rutherford categories I, II, and III) who were admitted between March 2020 and March 2022 for cardiovascular surgery or outpatient clinic follow-up were included. The patients (n = 60) were divided into 2 groups: medical treatment (n = 30) and surgical treatment (n = 30). In addition, a control group (n = 30) was created for comparison. Endocan, IL-17, and TSP-4 blood levels were measured at the time of diagnosis and at the first month after treatment. Endocan and IL-17 values were found to be significantly higher in both groups that underwent medical (259.7 ± 46 pg/mL, 63.7 ± 16.6 pg/mL) and surgical (290.3 ± 84.5 pg/mL, 66.4 ± 19.6 pg/mL) treatment than the control group (187.4 ± 34.5 pg/mL, 56.5 ± 7.2 pg/mL P < .001). Tsp-4 value was found to be significantly higher only in the surgical treatment group (15 ± 4.3 ng/mL) than the control group (12.9 ± 1.4 ng/mL P < .05). The decreases in endocan, IL-17, and TSP-4 levels at the first month of treatment in both groups were also significant (P < .001). A combination of classical and these new biomarkers could be included in PAD screening, early diagnosis, severity determination, and follow-up protocols in order to provide effective assessment in clinical practice. |
doi_str_mv | 10.1177/00033197231166492 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2794694111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_00033197231166492</sage_id><sourcerecordid>2794694111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EokvhAbggH4u0KZ7Yjuvj0j9QqQIk2nPkJJOu28QOnoSqL8Lz4tUWLkhoDp7x95vP8gxjb0EcAxjzQQghJVhTSoCqUrZ8xlZglShAG_WcrXZ6sQMO2Cuiu1xqENVLdiCNACGFXLFfX_CBf_RxdOkeE_Gj89DF1oU1vwwzpgGXex8KMGvuQsevtymOTaQphi5fq_e8j4nPW-Rn3t2GSJ7WfEOERCOGmceef8efmPz8uDe4iMMQH4qbaSd9y8K0xeQGvkn5MZ-TM0_oCF-zF70bCN88nYfs5uL8-vRzcfX10-Xp5qpopRJz0TXgOo2dOhG6E7ZpHVSN7trSikr2SjqRw1jtGln2J7aypbDGGA1aQ-uUkIfsaO87pfhjQZrr0VOLw-ACxoXq0lhVWQUAGYU92qZIlLCvp-Tz2B5rEPVuHfU_68g9757sl2bE7m_Hn_ln4HgPkLvF-i4uKeTv_sfxN5J3kaM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2794694111</pqid></control><display><type>article</type><title>New Biomarkers (Endocan, Interleukin-17, and Thrombospondin-4) for the Diagnosis, Assessment of Severity, and Follow-Up of Peripheral Arterial Disease</title><source>SAGE</source><creator>Yazman, Serkan ; Depboylu, Burak Can ; Saruhan, Ercan ; Cenikli, Utku ; Harmandar, Buğra ; Arslan, Kadir ; İlhan, Gökhan ; İştar, Hande</creator><creatorcontrib>Yazman, Serkan ; Depboylu, Burak Can ; Saruhan, Ercan ; Cenikli, Utku ; Harmandar, Buğra ; Arslan, Kadir ; İlhan, Gökhan ; İştar, Hande</creatorcontrib><description>The present study evaluated the use of endocan, interleukin-17 (IL-17), and thrombospondin-4 (TSP-4) blood levels as potential biomarkers for the diagnosis and follow-up of peripheral arterial disease (PAD). Patients with PAD (Rutherford categories I, II, and III) who were admitted between March 2020 and March 2022 for cardiovascular surgery or outpatient clinic follow-up were included. The patients (n = 60) were divided into 2 groups: medical treatment (n = 30) and surgical treatment (n = 30). In addition, a control group (n = 30) was created for comparison. Endocan, IL-17, and TSP-4 blood levels were measured at the time of diagnosis and at the first month after treatment. Endocan and IL-17 values were found to be significantly higher in both groups that underwent medical (259.7 ± 46 pg/mL, 63.7 ± 16.6 pg/mL) and surgical (290.3 ± 84.5 pg/mL, 66.4 ± 19.6 pg/mL) treatment than the control group (187.4 ± 34.5 pg/mL, 56.5 ± 7.2 pg/mL P < .001). Tsp-4 value was found to be significantly higher only in the surgical treatment group (15 ± 4.3 ng/mL) than the control group (12.9 ± 1.4 ng/mL P < .05). The decreases in endocan, IL-17, and TSP-4 levels at the first month of treatment in both groups were also significant (P < .001). A combination of classical and these new biomarkers could be included in PAD screening, early diagnosis, severity determination, and follow-up protocols in order to provide effective assessment in clinical practice.</description><identifier>ISSN: 0003-3197</identifier><identifier>EISSN: 1940-1574</identifier><identifier>DOI: 10.1177/00033197231166492</identifier><identifier>PMID: 37010303</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><ispartof>Angiology, 2023-08, Vol.74 (7), p.631-639</ispartof><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403</citedby><cites>FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403</cites><orcidid>0000-0002-6035-1123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37010303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yazman, Serkan</creatorcontrib><creatorcontrib>Depboylu, Burak Can</creatorcontrib><creatorcontrib>Saruhan, Ercan</creatorcontrib><creatorcontrib>Cenikli, Utku</creatorcontrib><creatorcontrib>Harmandar, Buğra</creatorcontrib><creatorcontrib>Arslan, Kadir</creatorcontrib><creatorcontrib>İlhan, Gökhan</creatorcontrib><creatorcontrib>İştar, Hande</creatorcontrib><title>New Biomarkers (Endocan, Interleukin-17, and Thrombospondin-4) for the Diagnosis, Assessment of Severity, and Follow-Up of Peripheral Arterial Disease</title><title>Angiology</title><addtitle>Angiology</addtitle><description>The present study evaluated the use of endocan, interleukin-17 (IL-17), and thrombospondin-4 (TSP-4) blood levels as potential biomarkers for the diagnosis and follow-up of peripheral arterial disease (PAD). Patients with PAD (Rutherford categories I, II, and III) who were admitted between March 2020 and March 2022 for cardiovascular surgery or outpatient clinic follow-up were included. The patients (n = 60) were divided into 2 groups: medical treatment (n = 30) and surgical treatment (n = 30). In addition, a control group (n = 30) was created for comparison. Endocan, IL-17, and TSP-4 blood levels were measured at the time of diagnosis and at the first month after treatment. Endocan and IL-17 values were found to be significantly higher in both groups that underwent medical (259.7 ± 46 pg/mL, 63.7 ± 16.6 pg/mL) and surgical (290.3 ± 84.5 pg/mL, 66.4 ± 19.6 pg/mL) treatment than the control group (187.4 ± 34.5 pg/mL, 56.5 ± 7.2 pg/mL P < .001). Tsp-4 value was found to be significantly higher only in the surgical treatment group (15 ± 4.3 ng/mL) than the control group (12.9 ± 1.4 ng/mL P < .05). The decreases in endocan, IL-17, and TSP-4 levels at the first month of treatment in both groups were also significant (P < .001). A combination of classical and these new biomarkers could be included in PAD screening, early diagnosis, severity determination, and follow-up protocols in order to provide effective assessment in clinical practice.</description><issn>0003-3197</issn><issn>1940-1574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQxi0EokvhAbggH4u0KZ7Yjuvj0j9QqQIk2nPkJJOu28QOnoSqL8Lz4tUWLkhoDp7x95vP8gxjb0EcAxjzQQghJVhTSoCqUrZ8xlZglShAG_WcrXZ6sQMO2Cuiu1xqENVLdiCNACGFXLFfX_CBf_RxdOkeE_Gj89DF1oU1vwwzpgGXex8KMGvuQsevtymOTaQphi5fq_e8j4nPW-Rn3t2GSJ7WfEOERCOGmceef8efmPz8uDe4iMMQH4qbaSd9y8K0xeQGvkn5MZ-TM0_oCF-zF70bCN88nYfs5uL8-vRzcfX10-Xp5qpopRJz0TXgOo2dOhG6E7ZpHVSN7trSikr2SjqRw1jtGln2J7aypbDGGA1aQ-uUkIfsaO87pfhjQZrr0VOLw-ACxoXq0lhVWQUAGYU92qZIlLCvp-Tz2B5rEPVuHfU_68g9757sl2bE7m_Hn_ln4HgPkLvF-i4uKeTv_sfxN5J3kaM</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Yazman, Serkan</creator><creator>Depboylu, Burak Can</creator><creator>Saruhan, Ercan</creator><creator>Cenikli, Utku</creator><creator>Harmandar, Buğra</creator><creator>Arslan, Kadir</creator><creator>İlhan, Gökhan</creator><creator>İştar, Hande</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6035-1123</orcidid></search><sort><creationdate>202308</creationdate><title>New Biomarkers (Endocan, Interleukin-17, and Thrombospondin-4) for the Diagnosis, Assessment of Severity, and Follow-Up of Peripheral Arterial Disease</title><author>Yazman, Serkan ; Depboylu, Burak Can ; Saruhan, Ercan ; Cenikli, Utku ; Harmandar, Buğra ; Arslan, Kadir ; İlhan, Gökhan ; İştar, Hande</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yazman, Serkan</creatorcontrib><creatorcontrib>Depboylu, Burak Can</creatorcontrib><creatorcontrib>Saruhan, Ercan</creatorcontrib><creatorcontrib>Cenikli, Utku</creatorcontrib><creatorcontrib>Harmandar, Buğra</creatorcontrib><creatorcontrib>Arslan, Kadir</creatorcontrib><creatorcontrib>İlhan, Gökhan</creatorcontrib><creatorcontrib>İştar, Hande</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Angiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yazman, Serkan</au><au>Depboylu, Burak Can</au><au>Saruhan, Ercan</au><au>Cenikli, Utku</au><au>Harmandar, Buğra</au><au>Arslan, Kadir</au><au>İlhan, Gökhan</au><au>İştar, Hande</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Biomarkers (Endocan, Interleukin-17, and Thrombospondin-4) for the Diagnosis, Assessment of Severity, and Follow-Up of Peripheral Arterial Disease</atitle><jtitle>Angiology</jtitle><addtitle>Angiology</addtitle><date>2023-08</date><risdate>2023</risdate><volume>74</volume><issue>7</issue><spage>631</spage><epage>639</epage><pages>631-639</pages><issn>0003-3197</issn><eissn>1940-1574</eissn><abstract>The present study evaluated the use of endocan, interleukin-17 (IL-17), and thrombospondin-4 (TSP-4) blood levels as potential biomarkers for the diagnosis and follow-up of peripheral arterial disease (PAD). Patients with PAD (Rutherford categories I, II, and III) who were admitted between March 2020 and March 2022 for cardiovascular surgery or outpatient clinic follow-up were included. The patients (n = 60) were divided into 2 groups: medical treatment (n = 30) and surgical treatment (n = 30). In addition, a control group (n = 30) was created for comparison. Endocan, IL-17, and TSP-4 blood levels were measured at the time of diagnosis and at the first month after treatment. Endocan and IL-17 values were found to be significantly higher in both groups that underwent medical (259.7 ± 46 pg/mL, 63.7 ± 16.6 pg/mL) and surgical (290.3 ± 84.5 pg/mL, 66.4 ± 19.6 pg/mL) treatment than the control group (187.4 ± 34.5 pg/mL, 56.5 ± 7.2 pg/mL P < .001). Tsp-4 value was found to be significantly higher only in the surgical treatment group (15 ± 4.3 ng/mL) than the control group (12.9 ± 1.4 ng/mL P < .05). The decreases in endocan, IL-17, and TSP-4 levels at the first month of treatment in both groups were also significant (P < .001). A combination of classical and these new biomarkers could be included in PAD screening, early diagnosis, severity determination, and follow-up protocols in order to provide effective assessment in clinical practice.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>37010303</pmid><doi>10.1177/00033197231166492</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6035-1123</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-3197 |
ispartof | Angiology, 2023-08, Vol.74 (7), p.631-639 |
issn | 0003-3197 1940-1574 |
language | eng |
recordid | cdi_proquest_miscellaneous_2794694111 |
source | SAGE |
title | New Biomarkers (Endocan, Interleukin-17, and Thrombospondin-4) for the Diagnosis, Assessment of Severity, and Follow-Up of Peripheral Arterial Disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A59%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Biomarkers%20(Endocan,%20Interleukin-17,%20and%20Thrombospondin-4)%20for%20the%20Diagnosis,%20Assessment%20of%20Severity,%20and%20Follow-Up%20of%20Peripheral%20Arterial%20Disease&rft.jtitle=Angiology&rft.au=Yazman,%20Serkan&rft.date=2023-08&rft.volume=74&rft.issue=7&rft.spage=631&rft.epage=639&rft.pages=631-639&rft.issn=0003-3197&rft.eissn=1940-1574&rft_id=info:doi/10.1177/00033197231166492&rft_dat=%3Cproquest_cross%3E2794694111%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c340t-db1ad5ed4805d09bca16b5dc29063f43a0a0a795ab32f896920977751551ca403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2794694111&rft_id=info:pmid/37010303&rft_sage_id=10.1177_00033197231166492&rfr_iscdi=true |